Anika Therapeutics (ANIK) Liabilities and Shareholders Equity (2010 - 2026)

Anika Therapeutics (ANIK) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $183.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 2.24% year-over-year to $183.5 million; the TTM figure through Jun 2026 stood at $742.6 million (down 8.6% YoY), while the FY2025 annual figure was $190.3 million, down 6.15% from the prior year.
• Liabilities and Shareholders Equity improved to $183.5 million in Q2 2026 per ANIK's latest filing, from $179.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $354.1 million in Q2 2022 and bottomed at $179.4 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $263.4 million across 5 years, with a median of $263.2 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity gained 0.46% — and 2024, when it retreated 29.48%.
• Anika Therapeutics' Liabilities and Shareholders Equity stood at $349.1 million in 2022, then slipped by 22.48% to $270.6 million in 2023, then decreased by 25.09% to $202.7 million in 2024, then slipped by 6.15% to $190.3 million in 2025, then declined by 3.57% to $183.5 million in 2026.
• Business Quant data shows ANIK's Liabilities and Shareholders Equity at $183.5 million in Q2 2026, $179.4 million in Q1 2026, and $190.3 million in Q4 2025.